# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Review Proposal Project**

# NICE Technology Appraisal no.151; Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

# Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Advanced Therapeutics UK (DANA  B. Ingulia Bump)	Association of British Healthcare Industries
R Insulin Pump)  Animas (Johnson & Johnson)	Board of Community Health Councils
(Animas 2020)	in Wales
Medtronic (Paradigm Veo)	Care Quality Commission
Roche Products (Accu-Chek	<ul> <li>Commissioning Support Appraisals</li> </ul>
Combo, Accu-Chek Spirit; Accu-	Service
Chek D-Tron Plus)	<ul> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> </ul>
Patient/carer groups	Diabetes UK Cymru
Action for Children	EUCOMED
Action for Sick Children	Medicines and Healthcare products
Afiya Trust	Regulatory Agency (MHRA)
<ul> <li>Black and Ethnic Minority Diabetes</li> </ul>	<ul> <li>National Association of Primary Care</li> </ul>
Association (BEMDA)	NHS Alliance
Black Health Agency	NHS Commercial Medicines Unit
Children's Society	NHS Confederation
Chinese National Healthy Living	NHS Quality Improvement Scotland
Centre	<ul> <li>Public Health Wales NHS Trust</li> </ul>
Counsel and Care	<ul> <li>Scottish Medicines Consortium</li> </ul>
Diabetes Research & Wellness	
Foundation	Possible comparator manufacturer(s)
Diabetes UK	Eli Lilly (insulin lispro)
Equalities National Council	Novo Nordisk (insulin detemir)
Healthier Weight Centres	<ul> <li>Sanofi Aventis (insulin glulisine,</li> </ul>
INPUT – Insulin Pump Therapy	insulin glargine)
Insulin Dependent Diabetes Trust	
Insulin Pumpers UK	Relevant research groups
Juvenile Diabetes Research	Diabetes Foundation
Foundation	Heart Disease and Diabetes
Muslim Council of Britain	Research Trust
Muslim Health Network	MRC Clinical Trials Unit
National Childbirth Trust	National Institute for Health Research
National Children's Bureau  National Institute for Health and Clinical Eventures.	<ul> <li>Policy Research Institute on Ageing and Ethnicity</li> </ul>

National Institute for Health and Clinical Excellence

NICE Technology Appraisal no.151; Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Issue date: March 2011

#### Consultees Commentators (no right to submit or appeal) Research Institute for the Care of National Obesity Forum National Parent Partnership Network Older People Network of Sikh Organisations **Assessment Group** South Asian Health Foundation Assessment Group tbc Specialised Healthcare Alliance National Institute for Health Research Surya Foundation Health Technology Assessment Weight Concern Programme WellChild **Associated Guideline Groups** Professional groups none Association for the Study of Obesity Association of British Clinical Associated Public Health Groups Diabetologists None Association of British Diabetes Specialist Nurses British Association for Services to the Elderly **British Diabetic Association British Geriatrics Society Diabetes Monitoring Forum** National Diabetes Nurse Consultant Group Primary Care Diabetes UK Royal College of General **Practitioners** Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine United Kingdom Clinical Pharmacy Association Others Department of Health **NHS Barnet** NHS Western Cheshire Welsh Assembly Government

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

National Institute for Health and Clinical Excellence

NICE Technology Appraisal no.151; Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Issue date: March 2011

#### **Definitions:**

# Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, Care Quality Commission and NHS Alliance, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute)

National Institute for Health and Clinical Excellence

NICE Technology Appraisal no.151; Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Issue date: March 2011

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.